The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation.

This study is using a specialized PET-CT scan (using a tracer called FCH) to better image prostate cancer in men who carry a known DNA repair gene mutation — such as BRCA1, BRCA2, or ATM. These genetic mutations affect how cancer grows and may make imaging-guided treatment more effective. **You may be eligible if...** - You are a man over 18 with a confirmed pathogenic mutation in one of these genes: BRCA1, BRCA2, MSH2, MSH6, MLH1, PMS2, CHEK2, PALB2, or ATM - You have been diagnosed with prostate cancer and imaging is clinically needed — either at new diagnosis, for a biochemical relapse after curative treatment, or if on active surveillance with a rapidly rising PSA **You may NOT be eligible if...** - You have had another cancer (other than minor skin cancer) within 5 years - You have known metastatic prostate cancer - You have received cancer treatment within the past 6 months - You are taking steroids - You have a contraindication to MRI (pacemaker, claustrophobia, etc.) - You have a history of inflammatory conditions like sarcoidosis or inflammatory bowel disease Talk to your doctor to see if this trial is right for you.